-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the State Food and Drug Administration's official website showed that Qilu Pharmaceutical's cefazolin sodium for injection has been approved as a supplementary application, and this product is the third domestically-evaluated company.
According to data from Meinenet, in 2020, the sales of cefazolin sodium for terminal injection in public medical institutions in China will exceed 1.
5 billion yuan.
There are more than 60 manufacturers of cefazolin sodium for injection.
At present, only Chengdu Better Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical and Qilu Pharmaceutical have been approved for supplementary applications.
It is worth mentioning that this product is the eighth injection product reviewed by Qilu Pharmaceutical in May.
At present, Qilu Pharmaceutical has 76 products passed or deemed to have passed the consistency evaluation, of which 35 are the first in China.
According to data from Meinenet, in 2020, the sales of cefazolin sodium for terminal injection in public medical institutions in China will exceed 1.
5 billion yuan.
There are more than 60 manufacturers of cefazolin sodium for injection.
At present, only Chengdu Better Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical and Qilu Pharmaceutical have been approved for supplementary applications.
It is worth mentioning that this product is the eighth injection product reviewed by Qilu Pharmaceutical in May.
At present, Qilu Pharmaceutical has 76 products passed or deemed to have passed the consistency evaluation, of which 35 are the first in China.
May 31, 2021 drug approval documents to be collected information released
Cefazolin sodium for injection belongs to the first-generation cephalosporin antibiotics.
It is clinically used to treat respiratory tract infections, urinary tract infections, bone and joint infections, sepsis and reproductive system infections caused by sensitive bacteria.
It is clinically used to treat respiratory tract infections, urinary tract infections, bone and joint infections, sepsis and reproductive system infections caused by sensitive bacteria.
Sales of Cefazolin Sodium for Terminal Injection in Public Medical Institutions in China in Recent Years
Source: The terminal competition pattern of China's public medical institutions
According to data from Meinenet, in recent years , the sales of cefazolin sodium for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have maintained a growth rate of more than 10% in 2020.
More than 1.
5 billion yuan.
Among them, China Resources Jiuxin Pharmaceutical, Shenzhen Lijian Pharmaceutical, and Chengdu Better Pharmaceutical have the top three market shares.
More than 1.
5 billion yuan.
Among them, China Resources Jiuxin Pharmaceutical, Shenzhen Lijian Pharmaceutical, and Chengdu Better Pharmaceutical have the top three market shares.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Sodium for Injection Cefazolin manufacturers have more than 60 at present, only Chengdu Brilliant Pharmaceutical, Guangdong Jincheng Kim Su pharmaceutical and Qilu Pharmaceutical three companies to supplement the application is approved through the comment.
In addition, the supplementary applications for consistency evaluation of 5 companies including Sinopharm Group Zhongnuo Pharmaceutical and Harbin Pharmaceutical Group Pharmaceutical General Factory are under review and approval.
Shenzhen China Resources Jiuxin Pharmaceutical | Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical has imitated 3 categories The submission of the listing application is under review and approval, and it will be deemed as over-evaluated after it is approved.
In addition, the supplementary applications for consistency evaluation of 5 companies including Sinopharm Group Zhongnuo Pharmaceutical and Harbin Pharmaceutical Group Pharmaceutical General Factory are under review and approval.
Shenzhen China Resources Jiuxin Pharmaceutical | Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical has imitated 3 categories The submission of the listing application is under review and approval, and it will be deemed as over-evaluated after it is approved.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
A few days ago, the State Food and Drug Administration's official website showed that Qilu Pharmaceutical's cefazolin sodium for injection has been approved as a supplementary application, and this product is the third domestically-evaluated company.
According to data from Meinenet, in 2020, the sales of cefazolin sodium for terminal injection in public medical institutions in China will exceed 1.
5 billion yuan.
There are more than 60 manufacturers of cefazolin sodium for injection.
At present, only Chengdu Better Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical and Qilu Pharmaceutical have been approved for supplementary applications.
It is worth mentioning that this product is the eighth injection product reviewed by Qilu Pharmaceutical in May.
At present, Qilu Pharmaceutical has 76 products passed or deemed to have passed the consistency evaluation, of which 35 are the first in China.
According to data from Meinenet, in 2020, the sales of cefazolin sodium for terminal injection in public medical institutions in China will exceed 1.
5 billion yuan.
There are more than 60 manufacturers of cefazolin sodium for injection.
At present, only Chengdu Better Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical and Qilu Pharmaceutical have been approved for supplementary applications.
It is worth mentioning that this product is the eighth injection product reviewed by Qilu Pharmaceutical in May.
At present, Qilu Pharmaceutical has 76 products passed or deemed to have passed the consistency evaluation, of which 35 are the first in China.
May 31, 2021 drug approval documents to be collected information released
Cefazolin sodium for injection belongs to the first-generation cephalosporin antibiotics.
It is clinically used to treat respiratory tract infections, urinary tract infections, bone and joint infections, sepsis and reproductive system infections caused by sensitive bacteria.
It is clinically used to treat respiratory tract infections, urinary tract infections, bone and joint infections, sepsis and reproductive system infections caused by sensitive bacteria.
Sales of Cefazolin Sodium for Terminal Injection in Public Medical Institutions in China in Recent Years
Source: The terminal competition pattern of China's public medical institutions
According to data from Meinenet, in recent years , the sales of cefazolin sodium for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have maintained a growth rate of more than 10% in 2020.
More than 1.
5 billion yuan.
Among them, China Resources Jiuxin Pharmaceutical, Shenzhen Lijian Pharmaceutical, and Chengdu Better Pharmaceutical have the top three market shares.
More than 1.
5 billion yuan.
Among them, China Resources Jiuxin Pharmaceutical, Shenzhen Lijian Pharmaceutical, and Chengdu Better Pharmaceutical have the top three market shares.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Sodium for Injection Cefazolin manufacturers have more than 60 at present, only Chengdu Brilliant Pharmaceutical, Guangdong Jincheng Kim Su pharmaceutical and Qilu Pharmaceutical three companies to supplement the application is approved through the comment.
In addition, the supplementary applications for consistency evaluation of 5 companies including Sinopharm Group Zhongnuo Pharmaceutical and Harbin Pharmaceutical Group Pharmaceutical General Factory are under review and approval.
Shenzhen China Resources Jiuxin Pharmaceutical | Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical has imitated 3 categories The submission of the listing application is under review and approval, and it will be deemed as over-evaluated after it is approved.
In addition, the supplementary applications for consistency evaluation of 5 companies including Sinopharm Group Zhongnuo Pharmaceutical and Harbin Pharmaceutical Group Pharmaceutical General Factory are under review and approval.
Shenzhen China Resources Jiuxin Pharmaceutical | Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical has imitated 3 categories The submission of the listing application is under review and approval, and it will be deemed as over-evaluated after it is approved.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
A few days ago, the State Food and Drug Administration's official website showed that Qilu Pharmaceutical's cefazolin sodium for injection has been approved as a supplementary application, and this product is the third domestically-evaluated company.
According to data from Meinenet, in 2020, the sales of cefazolin sodium for terminal injection in public medical institutions in China will exceed 1.
5 billion yuan.
There are more than 60 manufacturers of cefazolin sodium for injection.
At present, only Chengdu Better Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical and Qilu Pharmaceutical have been approved for supplementary applications.
It is worth mentioning that this product is the eighth injection product reviewed by Qilu Pharmaceutical in May.
At present, Qilu Pharmaceutical has 76 products passed or deemed to have passed the consistency evaluation, of which 35 are the first in China.
According to data from Meinenet, in 2020, the sales of cefazolin sodium for terminal injection in public medical institutions in China will exceed 1.
5 billion yuan.
There are more than 60 manufacturers of cefazolin sodium for injection.
At present, only Chengdu Better Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical and Qilu Pharmaceutical have been approved for supplementary applications.
It is worth mentioning that this product is the eighth injection product reviewed by Qilu Pharmaceutical in May.
At present, Qilu Pharmaceutical has 76 products passed or deemed to have passed the consistency evaluation, of which 35 are the first in China.
May 31, 2021 drug approval documents to be collected information released
Cefazolin sodium for injection belongs to the first-generation cephalosporin antibiotics.
It is clinically used to treat respiratory tract infections, urinary tract infections, bone and joint infections, sepsis and reproductive system infections caused by sensitive bacteria.
It is clinically used to treat respiratory tract infections, urinary tract infections, bone and joint infections, sepsis and reproductive system infections caused by sensitive bacteria.
Sales of Cefazolin Sodium for Terminal Injection in Public Medical Institutions in China in Recent Years
Source: The terminal competition pattern of China's public medical institutions
According to data from Meinenet, in recent years , the sales of cefazolin sodium for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have maintained a growth rate of more than 10% in 2020.
More than 1.
5 billion yuan.
Among them, China Resources Jiuxin Pharmaceutical, Shenzhen Lijian Pharmaceutical, and Chengdu Better Pharmaceutical have the top three market shares.
Hospital hospital hospitalMore than 1.
5 billion yuan.
Among them, China Resources Jiuxin Pharmaceutical, Shenzhen Lijian Pharmaceutical, and Chengdu Better Pharmaceutical have the top three market shares.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Sodium for Injection Cefazolin manufacturers have more than 60 at present, only Chengdu Brilliant Pharmaceutical, Guangdong Jincheng Kim Su pharmaceutical and Qilu Pharmaceutical three companies to supplement the application is approved through the comment.
In addition, the supplementary applications for consistency evaluation of 5 companies including Sinopharm Group Zhongnuo Pharmaceutical and Harbin Pharmaceutical Group Pharmaceutical General Factory are under review and approval.
Shenzhen China Resources Jiuxin Pharmaceutical | Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical has imitated 3 categories The submission of the listing application is under review and approval, and it will be deemed as over-evaluated after it is approved.
Enterprise business enterpriseIn addition, the supplementary applications for consistency evaluation of 5 companies including Sinopharm Group Zhongnuo Pharmaceutical and Harbin Pharmaceutical Group Pharmaceutical General Factory are under review and approval.
Shenzhen China Resources Jiuxin Pharmaceutical | Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical has imitated 3 categories The submission of the listing application is under review and approval, and it will be deemed as over-evaluated after it is approved.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
